Thus, PD-1/CTLA-4 blockade may be even more effective for controlling EBV-positive lymphomas in the context of certain types of human immunodeficiency (for example, following solid organ transplantation), where EBV-specific memory T cells and/or NK cells are present. This evidence concerns the gene CTLA4 and immune system disorder.